MGFB: vaccinating against tumor antigen escape

MGFB is developing virus-based cancer vaccines for solid tumors that prime the immune system against hundreds of tumor antigens, including ones that arise during tumor escape, and aims to achieve stronger immune responses by tapping non-human cDNA systems.

The clinical-stage company, a subsidiary of Greenfire Bio, launched Nov. 8 with technology licensed from Richard Vile’s lab at the Mayo Clinic.  ...